Fiche du document
- doi: 10.1093/ofid/ofaa323
- issn: 2328-8957
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1093/ofid/ofaa323
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/32913876
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/2328-8957
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_FAEE71EBE3B08
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Mots-clés
HIV; adherence intervention; antiretrovirals; interprofessionality; medication retention in careSujets proches
Care and treatmentCiter ce document
S. Kamal et al., « An Adherence-Enhancing Program Increases Retention in Care in the Swiss HIV Cohort. », Serveur académique Lausannois, ID : 10.1093/ofid/ofaa323
Métriques
Partage / Export
Résumé
This study tested a theory-based adherence-enhancing intervention: the "Interprofessional Medication Adherence Program" (IMAP) to increase human immunodeficiency virus (HIV) retention in care. We retrospectively compared our intervention center (intervention group [IG]) with a standard of care center (control group [CG]) both participating in the Swiss HIV Cohort Study between 2004 and 2012. Endpoints were defined as >6-month and >12-month gaps in care for intervals of care longer than 6 and 12 months without any blood draw. Inverse probability of treatment weights was used to adjust for differences between patients at the 2 centers. Viral failure was defined as ribonucleic acid ≥50 copies/mL after 24+ weeks on antiretrovirals. The IG included 451 patients, CG 311. In the IG, 179 (40%) patients took part in the IMAP for a median of 27 months (interquartile range, 12-45). Gaps in care of ≥6 months were significantly more likely to happen in the CG versus IG (74.6% vs 57%, P < .001). The median time until the first treatment gap was longer in the IG vs CG (120 vs 84 weeks, P < .001). Gaps in care of ≥12 months evaluated in 709 (93%) patients were significantly more likely to occur in the CG compared with the IG (22.6% vs 12.5%, P < .001). The rate of viral failure was significantly lower in the IG (8.3% vs 15.1%, P = .003). This study, in a real-world setting, shows the effectiveness of the IMAP to reduce 6- and 12-month gaps in follow up among people with HIV. These results should be confirmed by studies in other settings.